Q1 2027 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Consolidated revenue grew 17.5% year-over-year to INR2,545 crore, with hospital business revenue up 19%.
- Diagnostics business improved operating EBITDA margin to 23.9% from 23.0% year-over-year.
- Key specialties (renal sciences, neurosciences, orthopedics) saw strong revenue growth of 28%, 27%, and 23% respectively.
- Bed expansion progressing well, with 100 beds added in Q1 and plans for 400 more in the remaining quarters.
- International business revenue grew 13.3% year-over-year, contributing 8% to total revenue.
- Consolidated operating EBITDA margin declined to 22.3% from 22.6% year-over-year, impacted by recent acquisitions and ESOP costs.
- Hospital business EBITDA margin fell to 21.5% from 22.1% year-over-year, with new facilities negatively impacting margins by 0.2%.
- Oncology growth slowed significantly to ~5% due to government-mandated 30% discount on chemotherapy drugs, impacting specialty mix.
- Net debt increased to INR2,233 crore from INR1,869 crore year-over-year, raising net debt-to-EBITDA ratio to 1.01x.
- Diagnostics business growth (10.2%) lagged industry average (~15%), with management acknowledging muted growth and ongoing stabilization challenges.
(audio in progress) Healthcare Limited Q1 FY27 earnings conference call. (Operator Instructions)
I now hand the conference over to Mr. Anurag Kalra, Head of Investor Relations. Thank you, and over to you, sir.
Thank you, Aldric. Ladies and gentlemen, a very good morning and good afternoon, and thank you for taking the time to join us on our quarter one FY27 earnings call. The call is being chaired by our MD and CEO, Dr. Ashutosh Raghuvanshi. With him, we have our Chief Financial Officer, Mr. Vivek Goyal. From Agilus Diagnostics, we have the MD, Mr. Vijender Singh; and the Chief Financial Officer, Mr. Akshay Tiwari. We will start with some opening comments on the quarter one by Dr. Raghuvanshi. Post which, Mr. Vijender will take you through his thoughts on the diagnostics business for the quarter, and then we can open the floor for question and answers.
Over to Dr. Raghuvanshi.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
